Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on Novo Nordisk, what new FDA approval on its ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

The Food and Drug Administration approved Novo Nordisk’s popular weight-loss drug Wegovy to treat a [form of liver disease]( ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

Novo Nordisk (NVO) stock in focus as the company wins FDA accelerated nod for weight loss therapy Wegovy against the liver ...